• Reticulocyte Parameters and Hemoglobin F Production in Sickle Cell Disease Patients Undergoing Hydroxyurea Therapy
  • By R. Borba, C.S.P. Lima, and H.Z.W. Grotto- 2021-11-20


    Hemoglobin F (HbF) is an effective inhibitor of HbS polymerization. Hydroxyurea (HU) is used to increase HbF synthesis and improve the clinical course of sickle cell disease (SCD) patients. Higher values of Hb concentration, mean cell volume (MCV), mean cell hemoglobin (MCH), mean reticulocyte volume (MRV), HbF concentration, percentage of F-cells, and amount of HbF/ F-cells were observed in the treated group of patients. There was no correlation between Hb and HbF elevations. The reticulocyte count, immature reticulocyte
    count, mean fluorescence index (MFI), and neutrophil count were significantly lower in treated patients.

    Related file: